UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Adamis Pharmaceuticals Corporation
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
00547W307
(CUSIP Number)
August 1, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule
pursuant to which this Schedule is filed:
a. |
☐ |
Rule 13d-1(b) |
b. |
☒ |
Rule 13d-1(c) |
c. |
☐ |
Rule 13d-1(d) |
| * | The remainder of this cover page shall be filled
out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter the disclosures provided in a prior cover page.
|
The information required in the remainder of this cover page shall
not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise
subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
1. |
Names of Reporting Persons. |
|
|
|
Mitchell P. Kopin |
|
|
|
|
2. |
Check the Appropriate Box if a Member of a Group (See Instructions) |
|
|
|
(a) |
|
(b) |
|
|
|
|
3. |
SEC Use Only |
|
|
|
|
4. |
Citizenship or Place of Organization United States of America |
|
|
Number of
Shares Beneficially
Owned by Each
Reporting
Person With: |
|
5. Sole Voting Power 0 |
|
|
6. Shared Voting
Power 650,000 |
|
|
7. Sole Dispositive Power 0 |
|
|
8. Shared Dispositive
Power 650,000 |
|
|
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person 650,000 (see Item 4) |
|
|
|
|
10. |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) |
|
|
|
|
11. |
Percent of Class Represented by Amount in Row (9) 7.6% (see Item 4) |
|
|
|
|
12. |
Type of Reporting Person (See Instructions) |
|
|
|
IN; HC |
1. |
Names
of Reporting Persons. |
|
|
|
Daniel
B. Asher |
|
|
|
|
2. |
Check
the Appropriate Box if a Member of a Group (See Instructions) |
|
|
|
(a) |
|
(b) |
|
|
|
|
3. |
SEC
Use Only |
|
|
|
|
4. |
Citizenship
or Place of Organization United States of America |
|
|
Number of
Shares Beneficially
Owned by Each
Reporting
Person With: |
|
5. Sole Voting Power 0 |
|
|
6. Shared Voting
Power 650,000 |
|
|
7. Sole Dispositive Power 0 |
|
|
8. Shared Dispositive
Power 650,000 |
|
|
|
9. |
Aggregate
Amount Beneficially Owned by Each Reporting Person 650,000 (see Item 4) |
|
|
|
|
10. |
Check if the Aggregate Amount
in Row (9) Excludes Certain Shares (See Instructions) |
|
|
|
|
11. |
Percent of Class Represented by
Amount in Row (9) 7.6% (see Item 4) |
|
|
|
|
12. |
Type of Reporting Person (See
Instructions) |
|
|
|
IN;
HC |
1. |
Names
of Reporting Persons. |
|
|
|
Intracoastal Capital LLC |
|
|
|
|
2. |
Check
the Appropriate Box if a Member of a Group (See Instructions) |
|
|
|
(a) |
|
(b) |
|
|
|
|
3. |
SEC
Use Only |
|
|
|
|
4. |
Citizenship
or Place of Organization Delaware |
|
|
Number of
Shares Beneficially
Owned by Each
Reporting
Person With: |
|
5. Sole Voting Power 0 |
|
|
6. Shared Voting
Power 650,000 |
|
|
7. Sole Dispositive Power 0 |
|
|
8. Shared Dispositive
Power 650,000 |
|
|
|
9. |
Aggregate
Amount Beneficially Owned by Each Reporting Person 650,000 (see Item 4) |
|
|
|
|
10. |
Check if the Aggregate Amount
in Row (9) Excludes Certain Shares (See Instructions) |
|
|
|
|
11. |
Percent of Class Represented by
Amount in Row (9) 7.6% (see Item 4) |
|
|
|
|
12. |
Type of Reporting Person (See
Instructions) |
|
|
|
OO |
Item 1.
Adamis Pharmaceuticals Corporation (the “Issuer”)
| (b) | Address of Issuer’s Principal Executive Offices |
11682 El Camino Real, Suite
300
San Diego, California 92130
Item 2.
| (b) | Address of Principal Business Office or, if none, Residence |
This Schedule 13G is being filed on behalf
of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel
B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital
LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the
“Reporting Persons”).
The Reporting Persons have entered into
a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting
Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act
of 1934, as amended.
The principal business office of Mr. Kopin
and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.
The principal business office of Mr. Asher
is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.
| (d) | Title of Class of Securities |
Common Stock, $0.0001 par
value per share, of the Issuer (the “Common Stock”).
00547W307
Item 3. If this statement is filed pursuant
to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
Not applicable.
Item
4. Ownership.
(a) and (b):
(i) Immediately
following the execution of the Securities Purchase Agreement with the Issuer on August 1, 2023 (the “SPA”) (as disclosed
in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on August 3, 2023), each of the Reporting Persons may
have been deemed to have beneficial ownership of 309,699 shares of Common Stock, which consisted of (i) 300,000 shares of Common Stock
to be issued to Intracoastal at the closing of the transaction contemplated by the SPA and (ii) 9,699 shares of Common Stock issuable
upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal
Warrant 1”), and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 9.99% of the
Common Stock, based on (1) 2,790,396 shares of Common Stock outstanding as of August 1, 2023, as reported to the Reporting Persons by
the Issuer, plus (2) 300,000 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the
SPA and (3) 9,699 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 640,301 shares of
Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which
the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise
would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting
as a group together with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock, (II) 350,000 shares
of Common Stock issuable upon exercise of a second warrant to be issued to Intracoastal at the closing of the transaction contemplated
by the SPA (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder
thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result
in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together
with the holder or any of the holder’s affiliates, of more than 9.99% of the Common Stock and (III) 3,571 shares of Common Stock
issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 3”) because Intracoastal Warrant 3
contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but
only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates,
and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common
Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 1,303,571 shares
of Common Stock.
(ii) As
of the close of business on August 10, 2023, each of the Reporting Persons may have been deemed to have beneficial ownership of 650,000
shares of Common Stock issuable upon exercise of Intracoastal Warrant 1, and all such shares of Common Stock represented beneficial ownership
of approximately 7.6% of the Common Stock, based on (1) 2,790,396 shares of Common Stock outstanding as of August 1, 2023, as reported
to the Reporting Persons by the Issuer, plus (2) 4,800,000 shares of Common Stock in the aggregate issued at the closing of the transaction
contemplated by the SPA, (3) 350,000 shares of Common Stock issued to Intracoastal upon exercise of Intracoastal Warrant 2 and (4) 650,000
shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes 3,571 shares of Common Stock issuable
upon exercise of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does
not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial
ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the
holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provision, each of the Reporting
Persons may have been deemed to have beneficial ownership of 653,571 shares of Common Stock.
| (c) | Number of shares as to which each Reporting Person has: |
(i) Sole power
to vote or to direct the vote: 0.
(ii) Shared power
to vote or to direct the vote: 650,000.
(iii) Sole power
to dispose or to direct the disposition of 0.
(iv) Shared power
to dispose or to direct the disposition of 650,000.
| Item 5. | Ownership of Five Percent or Less of a Class |
Not applicable.
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
Not applicable.
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security
Being Reported on By the Parent Holding Company |
Not applicable.
| Item 8. | Identification and Classification of Members of the Group |
Not applicable.
| Item 9. | Notice of Dissolution of Group |
Not applicable.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the
control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction
having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: August 10, 2023
|
/s/ Mitchell P. Kopin |
|
Mitchell P. Kopin |
|
|
|
/s/ Daniel B. Asher |
|
Daniel B. Asher |
|
|
|
Intracoastal Capital LLC |
|
|
|
By: |
/s/ Mitchell P. Kopin |
|
|
Mitchell P. Kopin, Manager |
Page 7 of 7
Exhibit 1
JOINT FILING AGREEMENT
The undersigned acknowledge
and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments
to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing
agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness
and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and
accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information
is inaccurate.
Date: August 10, 2023
|
/s/ Mitchell P. Kopin |
|
Mitchell P. Kopin |
|
|
|
/s/ Daniel B. Asher |
|
Daniel B. Asher |
|
|
|
Intracoastal Capital LLC |
|
|
|
By: |
/s/ Mitchell P. Kopin |
|
|
Mitchell P. Kopin, Manager |
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024